PubMed:23326008 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/PubMed/sourceid/23326008","sourcedb":"PubMed","sourceid":"23326008","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/23326008","text":"Reirradiation of recurrent head and neck cancer using high-dose-rate brachytherapy.\nThe aim of the present study was to evaluate the results of hypofractionated accelerated CT-guided interstitial HDR-BRT using 2.5 Gy per fraction. From December 2008 to March 2010, 30 patients were treated for recurrence of previously-irradiated head and neck cancer. Thirteen patients underwent surgical resection followed by HDR-BRT to the tumour bed. Seventeen patients were treated with HDR-BRT only. All patients received 2.5 Gy twice per day for a total dosage of 30 Gy. The overall survival rate (OS) for the entire group at 1 and 2-years was 63% and 47%, while local control (LC) was 73% and 67%, and disease-free survival (DFS) was 60% and 53%, respectively. Patients treated with surgical resection and HDR-BRT showed an improvement in both 2-year LC (77% vs. 47%, p = 0.013) and 2-year OS (62% vs. 35%, p = 0.035) compared to patients treated with HDR-BRT only. Median OS for pre-treatment tumour volumes ≤ 36 cm3 was 22 months and 9.2 months for those \u003e 36 cm3 (p = 0.038). Grade III and IV late complications occurred in 3% of patients. There were no grade V complications. The interstitial HDR brachytherapy regimen using 2.5 Gy twice daily fractions at a total dose of 30 Gy offers an effective treatment option for patients with recurrent previously-irradiated head and neck cancer with a low rate of late high grade toxicity. Surgical resection had a positive effect on survival and local control in management of patients with recurrent head and neck cancer.","tracks":[{"project":"Allie","denotations":[{"id":"SS1_23326008_6_0","span":{"begin":565,"end":586},"obj":"expanded"},{"id":"SS2_23326008_6_0","span":{"begin":588,"end":590},"obj":"abbr"},{"id":"SS1_23326008_6_1","span":{"begin":653,"end":666},"obj":"expanded"},{"id":"SS2_23326008_6_1","span":{"begin":668,"end":670},"obj":"abbr"},{"id":"SS1_23326008_6_2","span":{"begin":693,"end":714},"obj":"expanded"},{"id":"SS2_23326008_6_2","span":{"begin":716,"end":719},"obj":"abbr"}],"relations":[{"id":"AE1_23326008_6_0","pred":"abbreviatedTo","subj":"SS1_23326008_6_0","obj":"SS2_23326008_6_0"},{"id":"AE1_23326008_6_1","pred":"abbreviatedTo","subj":"SS1_23326008_6_1","obj":"SS2_23326008_6_1"},{"id":"AE1_23326008_6_2","pred":"abbreviatedTo","subj":"SS1_23326008_6_2","obj":"SS2_23326008_6_2"}],"attributes":[{"subj":"SS1_23326008_6_0","pred":"source","obj":"Allie"},{"subj":"SS2_23326008_6_0","pred":"source","obj":"Allie"},{"subj":"SS1_23326008_6_1","pred":"source","obj":"Allie"},{"subj":"SS2_23326008_6_1","pred":"source","obj":"Allie"},{"subj":"SS1_23326008_6_2","pred":"source","obj":"Allie"},{"subj":"SS2_23326008_6_2","pred":"source","obj":"Allie"}]},{"project":"PubmedHPO","denotations":[{"id":"T1","span":{"begin":344,"end":350},"obj":"HP_0002664"},{"id":"T2","span":{"begin":426,"end":432},"obj":"HP_0002664"},{"id":"T3","span":{"begin":985,"end":991},"obj":"HP_0002664"},{"id":"T4","span":{"begin":1375,"end":1381},"obj":"HP_0002664"},{"id":"T5","span":{"begin":1553,"end":1559},"obj":"HP_0002664"}],"attributes":[{"subj":"T1","pred":"source","obj":"PubmedHPO"},{"subj":"T2","pred":"source","obj":"PubmedHPO"},{"subj":"T3","pred":"source","obj":"PubmedHPO"},{"subj":"T4","pred":"source","obj":"PubmedHPO"},{"subj":"T5","pred":"source","obj":"PubmedHPO"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"Allie","color":"#b4ec93","default":true},{"id":"PubmedHPO","color":"#ec93ce"}]}]}}